Company profile for NuGenerex

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Hema Diagnostic Systems (HDS) is a manufacturer of in-vitro medical diagnostic devices for both point of care and laboratory-based tests, primarily for infectious diseases. Established in Miami, Florida on December 1, 2000, HDS is currently headquartered in Miramar, Florida. Strategically, the Company’s mission has been to develop, manufacture and market a series of diagnostic tests that yields repeatable and reliable test ...
Hema Diagnostic Systems (HDS) is a manufacturer of in-vitro medical diagnostic devices for both point of care and laboratory-based tests, primarily for infectious diseases. Established in Miami, Florida on December 1, 2000, HDS is currently headquartered in Miramar, Florida. Strategically, the Company’s mission has been to develop, manufacture and market a series of diagnostic tests that yields repeatable and reliable test results for an antibody or antigenic response to a specific disease in such samples as whole blood, plasma, or serum.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Miramar, Florida 33025
Telephone
Telephone
+1-954- 919-5123
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

International Sweetener Colloquium

Not Confirmed

envelop Contact Supplier

International Sweetener Colloquium

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2021/06/22/2251174/0/en/NuGenerex-Immuno-Oncology-Secures-535-Million-Valuation-from-World-Class-Independent-Valuation-Appraisal-Firm.html

GLOBENEWSWIRE
22 Jun 2021

http://www.globenewswire.com/news-release/2020/11/23/2131844/0/en/Generex-and-NuGenerex-Immuno-Oncology-Ii-Key-SARS-CoV-2-Vaccine-Partner-Bintai-Kinden-Executes-its-Exclusive-Distribution-Licensing-Option-for-Australia-and-New-Zealand.html

GLOBENEWSWIRE
23 Nov 2020

https://www.nasdaq.com/press-release/nugenerex-immuno-oncology-announces-closing-of-a-licensing-distribution-agreement

NASDAQ
07 Oct 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty